These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 21182629)

  • 41. Frozen red blood cells: cold comfort in a disaster?
    Ramsey G
    Transfusion; 2008 Oct; 48(10):2053-5. PubMed ID: 18928507
    [No Abstract]   [Full Text] [Related]  

  • 42. The red blood cell storage lesion: the end of the beginning.
    Glynn SA; Klein HG; Ness PM
    Transfusion; 2016 Jun; 56(6):1462-8. PubMed ID: 27080455
    [No Abstract]   [Full Text] [Related]  

  • 43. Effect of L-carnitine during storage of buffy-coat platelet concentrates in an additive solution.
    Aleil B; Isola H; Cazenave JP
    Vox Sang; 2005 Jul; 89(1):59-60. PubMed ID: 15938742
    [No Abstract]   [Full Text] [Related]  

  • 44. Effects of Mirasol PRT treatment on storage lesion development in plasma-stored apheresis-derived platelets compared to untreated and irradiated units.
    Picker SM; Steisel A; Gathof BS
    Transfusion; 2008 Aug; 48(8):1685-92. PubMed ID: 18513255
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Platelet ADP response deteriorates in synthetic storage media.
    Keuren JF; Cauwenberghs S; Heeremans J; de Kort W; Heemskerk JW; Curvers J
    Transfusion; 2006 Feb; 46(2):204-12. PubMed ID: 16441596
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reduction in adverse reactions to platelets by the removal of plasma supernatant and resuspension in a new additive solution (M-sol).
    Azuma H; Hirayama J; Akino M; Miura R; Kiyama Y; Imai K; Kasai M; Koizumi K; Kakinoki Y; Makiguchi Y; Kubo K; Atsuta Y; Fujihara M; Homma C; Yamamoto S; Kato T; Ikeda H
    Transfusion; 2009 Feb; 49(2):214-8. PubMed ID: 18798806
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Extended platelet storage makes a welcome difference.
    Townsend L
    MLO Med Lab Obs; 2007 Jun; 39(6):40-1. PubMed ID: 17691706
    [No Abstract]   [Full Text] [Related]  

  • 48. The efficacy of synthetic media in the storage of human platelets for transfusion.
    Murphy S
    Transfus Med Rev; 1999 Jul; 13(3):153-63. PubMed ID: 10425688
    [No Abstract]   [Full Text] [Related]  

  • 49. General overview of blood products in vitro quality: Processing and storage lesions.
    Abonnenc M; Tissot JD; Prudent M
    Transfus Clin Biol; 2018 Nov; 25(4):269-275. PubMed ID: 30241785
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Quality of platelet concentrates derived by platelet rich plasma, buffy coat and Apheresis.
    Vasconcelos E; Figueiredo AC; Seghatchian J
    Transfus Apher Sci; 2003 Aug; 29(1):13-6. PubMed ID: 12877887
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Platelet transfusions.
    Kelton JG; Blajchman MA
    Can Med Assoc J; 1979 Nov; 121(10):1353-8. PubMed ID: 391376
    [TBL] [Abstract][Full Text] [Related]  

  • 52. National French observatory of the quality of blood components for transfusion.
    Chabanel A; Masse M; Begue S;
    Transfus Clin Biol; 2008 Jun; 15(3):85-90. PubMed ID: 18524661
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Assessment of biofilm-forming ability of coagulase-negative staphylococci isolated from contaminated platelet preparations in Canada.
    Greco C; Mastronardi C; Pagotto F; Mack D; Ramirez-Arcos S
    Transfusion; 2008 May; 48(5):969-77. PubMed ID: 18346023
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet light.
    Mohr H; Steil L; Gravemann U; Thiele T; Hammer E; Greinacher A; Müller TH; Völker U
    Transfusion; 2009 Dec; 49(12):2612-24. PubMed ID: 19682340
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Automation in the preparation of labile blood products].
    Tardivel R; Bois S; Vignoli C; Naegelen C; Isola H
    Transfus Clin Biol; 2009 May; 16(2):175-8. PubMed ID: 19446485
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Bacterial growth of thrombocyte preparations during storage time].
    Karakassopoulos A; Sobek-Pfeiffer C; Bösenberg H; Müller N
    Beitr Infusionsther; 1990; 26():112-6. PubMed ID: 1703807
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison between in vitro qualities of platelets washed with commercially available additive solutions and those washed with M-sol.
    Hirayama J; Azuma H; Fujihara M; Akino M; Homma C; Kato T; Ikeda H
    Vox Sang; 2010 Aug; 99(2):131-5. PubMed ID: 20497408
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An approach to prevent the severe adverse events associated with transfusion of FDA-approved blood products.
    Valeri CR; Ragno G
    Transfus Apher Sci; 2010 Jun; 42(3):223-33. PubMed ID: 20392670
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Platelet additive solutions: current status.
    Gulliksson H
    Immunohematology; 2007; 23(1):14-9. PubMed ID: 17425411
    [No Abstract]   [Full Text] [Related]  

  • 60. Conventional blood banking and blood component storage regulation: opportunities for improvement.
    Hess JR
    Blood Transfus; 2010 Jun; 8 Suppl 3(Suppl 3):s9-15. PubMed ID: 20606757
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.